LUNG has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LUNG has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Pulmonx's PE Ratio without NRI is 0.00. Pulmonx's 5-Year EBITDA growth rate is -1.00%. Therefore, Pulmonx's PEG Ratio for today is N/A.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Pulmonx's PEG Ratio or its related term are showing as below:
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
The historical data trend for Pulmonx's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulmonx Annual Data | ||||||||||||||||
Trend | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||
PEG Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Pulmonx Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
PEG Ratio | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Medical Devices subindustry, Pulmonx's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Pulmonx's PEG Ratio falls into.
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.
Pulmonx's PEG Ratio for today is calculated as
PEG Ratio | = | PE Ratio without NRI | / | 5-Year EBITDA Growth Rate* |
= | / | -1.00 | ||
= | N/A |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Pulmonx (NAS:LUNG) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Thank you for viewing the detailed overview of Pulmonx's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
David Aaron Lehman | officer: General Counsel | C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025 |
Geoffrey Beran Rose | officer: Chief Commercial Officer | 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016 |
French Glendon E. Iii | director, officer: President and CEO | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
John Mckune | officer: Interim CFO | 46668 CRAWFORD CT., FREMONT CA 94539 |
Derrick Sung | officer: Chief Financial Officer | C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103 |
Alissa Hsu Lynch | director | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Richard M Ferrari | director | 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050 |
Tiffany Sullivan | director | 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Boston Scientific Corp | 10 percent owner | 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Daniel P Florin | director | 56 E. BELL DRIVE, WARSAW IN 46581 |
Mead Dana G Jr. | director | 2750 SAND HILL ROAD, MENLO PARK CA 94025 |
Thomas William Burns | director | C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653 |
Georgia Melenikiotou | director | C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416 |
Staffan Lindstrand | director | C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51 |
From GuruFocus
By Marketwired • 11-20-2024
By Marketwired • 11-05-2024
By Marketwired • 02-13-2025
By GuruFocus News • 02-19-2025
By Marketwired • 11-07-2024
By GuruFocus News • 02-20-2025
By Marketwired • 08-22-2024
By Marketwired • 05-06-2024
By Marketwired • 02-19-2025
By Marketwired • 07-10-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.